Содержание
- 2. Major Entry Criteria V-HeFT I and V-HeFT II Inclusion criteria Men, 18 to 75 yr old
- 3. Placebo Isosorbide dinitrate 40 mg qid Enalapril 10 mg bid Prazosin 5 mg qid V-HeFT I
- 4. Study Endpoints V-HeFT I and V-HeFT II Major endpoints All-cause mortality during entire study All-cause mortality
- 5. Survival in All Patients V-HeFT I ISDN/HYD, n = 186 148 109 71 37 16 Placebo,
- 6. DV Final NDA20-727_BD.pdf T 3 and pg 26, 24T3 Survival in All Patients V-HeFT I 26
- 7. 26 DV Final NDA20-727_Brief_Document.pdf F 8 Survival in All Patients V-HeFT II ISDN/HYD, n = 401
- 8. Survival in All Patients V-HeFT II 26 DV Final NDA20-727_Brief_Document.pdf page 46
- 9. Subgroup Analysis
- 10. Survival in Black Patients and White Patients V-HeFT II Black patients White patients DV Final NDA20-727_Brief_Document.pdf
- 11. Survival in Black Patients and White Patients V-HeFT I DV Final NDA20-727_Brief_Document.pdf F 3 Black patients
- 12. V-HeFT I—Conclusions (1) ISDN/HYD compared to placebo was associated with A 22% lower risk of death
- 13. V-HeFT II—Conclusions (2) Enalapril compared to ISDN/HYD was associated with A 23% lower mortality overall (P
- 15. Скачать презентацию